Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

22 trials with published results (7%)

Research Maturity

116 completed trials (39% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.7%

8 terminated out of 297 trials

Success Rate

93.5%

+7.0% vs benchmark

Late-Stage Pipeline

6%

17 trials in Phase 3/4

Results Transparency

19%

22 of 116 completed with results

Key Signals

22 with results94% success

Data Visualizations

Phase Distribution

196Total
Not Applicable (66)
Early P 1 (30)
P 1 (65)
P 2 (18)
P 3 (8)
P 4 (9)

Trial Status

Completed116
Recruiting81
Unknown43
Not Yet Recruiting25
Withdrawn9
Terminated8

Trial Success Rate

93.5%

Benchmark: 86.5%

Based on 116 completed trials

Clinical Trials (297)

Showing 20 of 20 trials
NCT06948110RecruitingPrimary

Deciphering the Genetic Architecture of Autoimmune Diseases

NCT06502015Recruiting

Biomarkers in Autoimmune Disease of Nervous System

NCT07490951Not ApplicableRecruitingPrimary

A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases

NCT07699380Phase 2Recruiting

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

NCT04656873Completed

Immuno-Oncology Database and Bioregistry

NCT07604792Early Phase 1SuspendedPrimary

FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.

NCT01351545Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT04297592Phase 4Enrolling By Invitation

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

NCT07674147Early Phase 1Not Yet RecruitingPrimary

RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases

NCT04978948RecruitingPrimary

Study of STIM1 Membrane Expression

NCT06382675Not ApplicableRecruitingPrimary

Clinical Performance of the New Plasma Filter PX2 in TPE Treatments

NCT06435897Phase 1RecruitingPrimary

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

NCT05459870Phase 1RecruitingPrimary

CAR-T Cells Targeting Autoimmune Diseases

NCT06342713Phase 1Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT03490539Completed

Disease-Modifying Treatments for Myasthenia Gravis

NCT06736587Phase 1RecruitingPrimary

Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers

NCT07513181Phase 2Not Yet Recruiting

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

NCT04663204Phase 2Recruiting

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

NCT07455578Phase 1RecruitingPrimary

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT07613411Early Phase 1Not Yet RecruitingPrimary

Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases

Scroll to load more

Research Network

Activity Timeline